Identification

Name
Etomidate
Accession Number
DB00292  (APRD00965)
Type
Small Molecule
Groups
Approved
Description

Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic. [PubChem]

Structure
Thumb
Synonyms
  • (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
  • (+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
  • (+)-etomidate
  • (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
  • (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
  • 3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
  • Etomidate
  • Etomidato
  • Etomidatum
  • R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmidateInjection, solution2 mg/mLIntravenousGeneral Injectables & Vaccines2010-03-102017-09-29Us
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-07Not applicableUs
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-072017-04-19Us
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-07Not applicableUs
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-072017-04-19Us
AmidateInjection, solution2 mg/mLIntravenousGeneral Injectables & Vaccines2010-08-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EtomidateInjection2 mg/mLIntravenousHeritage2012-09-13Not applicableUs
EtomidateSolution2 mg/mLIntravenousGland Pharma Limited2017-05-20Not applicableUs
EtomidateInjection, solution40 mg/20mLIntravenousAuro Medics Pharma Llc2017-02-24Not applicableUs
EtomidateInjection2 mg/mLIntravenousWest Ward Pharmaceutical2016-02-25Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousMylan Institutional2012-02-03Not applicableUs
EtomidateInjection2 mg/mLIntravenousWest Ward Pharmaceutical2016-02-25Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousAthenex Pharmaceutical Division, Llc.2017-08-01Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousPharma Force, Inc.2010-06-082016-10-13Us
EtomidateInjection, solution2 mg/mLIntravenousAmerican Regent2010-06-302018-05-11Us
EtomidateInjection, solution20 mg/10mLIntravenousAuro Medics Pharma Llc2017-02-24Not applicableUs
International/Other Brands
Hypnomidate (Janssen)
Categories
UNII
Z22628B598
CAS number
33125-97-2
Weight
Average: 244.289
Monoisotopic: 244.121177766
Chemical Formula
C14H16N2O2
InChI Key
NPUKDXXFDDZOKR-LLVKDONJSA-N
InChI
InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1
IUPAC Name
ethyl 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate
SMILES
CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1

Pharmacology

Indication

Used in the induction of general anesthesia.

Associated Therapies
Pharmacodynamics

Etomidate is a non-barbiturate hypnotic that acts at the level of the reticular-activating system to produce anesthesia. Etomidate is an imidazole compound that appears to depress CNS function via GABA. Duration of action is intermediate between thiopental and methohexital, and recovery from a single dose is rapid with little residual depression. Like the barbiturates and propofol, etomidate is does not induce analgesia. Etomidate induces unconsciousness within one circulation time. Recovery is rapid as a result of extensive redistribution and rapid metabolism.

Mechanism of action

Etomidate binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
agonist
Human
AAlpha-2B adrenergic receptor
agonist
Human
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

76%, primarily to serum albumin.

Metabolism

Hepatic. Metabolized rapidly by ester hydrolysis to inactive metabolites.

Route of elimination

Approximately 75% of the administered dose is excreted in the urine during the first day after injection.

Half life

75 minutes.

Clearance
Not Available
Toxicity

Undesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Etomidate is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Etomidate is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Etomidate is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Etomidate is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Etomidate is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Etomidate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcebutololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Acebutolol.Approved, Investigational
AcepromazineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Etomidate is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Etomidate is combined with Acetylglycinamide chloral hydrate.Experimental
AdinazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Etomidate is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Etomidate is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Etomidate is combined with Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Etomidate.Approved, Illicit
AlfuzosinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Alfuzosin.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Etomidate is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Etomidate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Etomidate is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etomidate.Approved, Illicit, Investigational
AlprenololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Etomidate is combined with Alverine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Etomidate is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of hypertension can be increased when Amineptine is combined with Etomidate.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Amisulpride.Approved, Investigational
AmitriptylineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Amitriptyline.Approved
AmitriptylinoxideThe risk or severity of hypertension can be increased when Amitriptylinoxide is combined with Etomidate.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etomidate.Approved, Illicit
AmoxapineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Etomidate is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Amphetamine.Approved, Illicit, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Etomidate is combined with Aniracetam.Experimental
AnisodamineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Anisodamine.Investigational
APD791The risk or severity of adverse effects can be increased when Etomidate is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Etomidate is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Etomidate is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Etomidate is combined with Arbekacin.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Etomidate can be decreased when used in combination with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe therapeutic efficacy of Etomidate can be decreased when used in combination with Aripiprazole lauroxil.Approved, Investigational
ArotinololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Arotinolol.Investigational
AsenapineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Asenapine.Approved
AtenololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Atenolol.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Etomidate is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Etomidate is combined with Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Azaperone.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when Etomidate is combined with AZD-3043.Investigational
AzelastineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Etomidate.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Etomidate is combined with Beclamide.Experimental
BefunololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Befunolol.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Etomidate is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Etomidate is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Benperidol.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineEtomidate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetaxololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Betaxolol.Approved, Investigational
BevantololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Bevantolol.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Etomidate is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Etomidate is combined with Bifeprunox.Investigational
BisoprololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Bisoprolol.Approved
BL-1020The risk or severity of adverse effects can be increased when Etomidate is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Blonanserin.Approved, Investigational
BopindololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Bopindolol.Approved
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Etomidate is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Etomidate is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Etomidate can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Etomidate is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Etomidate is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etomidate.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Etomidate is combined with Bromisoval.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Etomidate.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Etomidate.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Bucindolol.Investigational
BufotenineThe risk or severity of adverse effects can be increased when Etomidate is combined with Bufotenine.Experimental, Illicit
BufuralolThe therapeutic efficacy of Etomidate can be decreased when used in combination with Bufuralol.Experimental, Investigational
BunazosinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Bunazosin.Investigational
BupranololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Bupranolol.Approved
BuprenorphineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Etomidate is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Etomidate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etomidate.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Etomidate.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Etomidate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etomidate.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of hypertension can be increased when Butriptyline is combined with Etomidate.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Etomidate.Approved
CamazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Camazepam.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Etomidate is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Etomidate is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Etomidate is combined with Captodiame.Approved, Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etomidate.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Etomidate.Approved
CarbromalThe risk or severity of adverse effects can be increased when Etomidate is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Etomidate.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Caroxazone.Withdrawn
CarteololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Carteolol.Approved
CarvedilolThe therapeutic efficacy of Etomidate can be decreased when used in combination with Carvedilol.Approved, Investigational
CathinoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Cathinone.Illicit
CeliprololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Celiprolol.Approved, Investigational
CerlapirdineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Etomidate.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Etomidate.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etomidate.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorproethazine.Experimental
ChlorpromazineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Etomidate.Approved
CilansetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Cilansetron.Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Etomidate is combined with Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Etomidate is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Etomidate.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Etomidate.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Etomidate.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of hypertension can be increased when Clomipramine is combined with Etomidate.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Etomidate.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Etomidate.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Etomidate is combined with Clopenthixol.Experimental
CloranololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etomidate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Clotiazepam.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Cloxazolam.Approved, Investigational
ClozapineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Etomidate.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Etomidate is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Etomidate is combined with Colistin.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Etomidate.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of hypertension can be increased when Cyclobenzaprine is combined with Etomidate.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Etomidate.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Etomidate.Approved, Investigational
DapiprazoleThe therapeutic efficacy of Etomidate can be decreased when used in combination with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapoxetine.Investigational
DeanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Decamethonium.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Etomidate is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Etomidate.Approved
DesipramineThe risk or severity of hypertension can be increased when Desipramine is combined with Etomidate.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etomidate.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Etomidate is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Etomidate is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etomidate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextofisopam.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Etomidate.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Etomidate is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of hypertension can be increased when Dibenzepin is combined with Etomidate.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Etomidate is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Etomidate.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etomidate.Approved, Illicit
DihydroergocornineDihydroergocornine may increase the hypertensive and vasoconstricting activities of Etomidate.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive and vasoconstricting activities of Etomidate.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive and vasoconstricting activities of Etomidate.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Etomidate.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydrostreptomycin.Investigational, Vet Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etomidate.Approved
DimetacrineThe risk or severity of hypertension can be increased when Dimetacrine is combined with Etomidate.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etomidate.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etomidate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dixyrazine.Experimental
DolasetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Etomidate is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Etomidate is combined with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Etomidate is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of hypertension can be increased when Dosulepin is combined with Etomidate.Approved
DotarizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Etomidate is combined with Doxacurium.Approved
DoxazosinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Doxazosin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Doxefazepam.Experimental
DoxepinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Doxepin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Etomidate is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Illicit
DronedaroneThe therapeutic efficacy of Etomidate can be decreased when used in combination with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Etomidate is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Edivoxetine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Etomidate.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Etomidate is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Etomidate.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Etomidate.Approved, Investigational
EpanololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Etomidate is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Eplivanserin.Investigational
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Etomidate.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Etomidate.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Etomidate.Approved
EsatenololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Esatenolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Etomidate is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Etomidate is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Esmirtazapine.Investigational
EsmololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Esmolol.Approved
EsreboxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Etomidate.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etomidate.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etomidate is combined with Etacrynic acid.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethadione.Experimental
EthanolEtomidate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etomidate.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Etomidate.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Etomidate.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etomidate is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Etizolam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Etomidate.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Etomidate is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Etomidate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etomidate.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Fenyramidol.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Etomidate.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Etomidate.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Etomidate.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe therapeutic efficacy of Etomidate can be decreased when used in combination with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etomidate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etomidate.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Etomidate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Etomidate.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Etomidate is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Etomidate is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Etomidate is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etomidate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Etomidate.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Etomidate is combined with Gaboxadol.Investigational
GallamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Etomidate is combined with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Etomidate.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Etomidate is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Etomidate is combined with Gedocarnil.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Etomidate is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Etomidate is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Etomidate is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Etomidate is combined with Glutethimide.Approved, Illicit
GranisetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Etomidate.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etomidate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Etomidate is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Etomidate is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Etomidate is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Etomidate is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Hexobarbital.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Etomidate.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Hydracarbazine.Experimental
HydrocodoneEtomidate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etomidate.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Etomidate is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Etomidate is combined with Hypericin.Investigational
IdalopirdineThe risk or severity of adverse effects can be increased when Etomidate is combined with Idalopirdine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Etomidate is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Iferanserin.Investigational
IloperidoneThe therapeutic efficacy of Etomidate can be decreased when used in combination with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Etomidate is combined with Imagabalin.Investigational
ImipramineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Imipramine.Approved
Imipramine oxideThe risk or severity of hypertension can be increased when Imipramine oxide is combined with Etomidate.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Etomidate is combined with Indalpine.Investigational, Withdrawn
IndenololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Etomidate is combined with Indiplon.Investigational
IndoraminThe therapeutic efficacy of Etomidate can be decreased when used in combination with Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Etomidate.Approved, Investigational
IprazochromeThe risk or severity of adverse effects can be increased when Etomidate is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of hypertension can be increased when Iprindole is combined with Etomidate.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Etomidate is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Etomidate is combined with Iproniazid.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when Etomidate is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Etomidate is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Etomidate.Approved, Vet Approved
KanamycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etomidate.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketobemidone.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when Etomidate is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolThe therapeutic efficacy of Etomidate can be decreased when used in combination with Labetalol.Approved
LacosamideThe risk or severity of adverse effects can be increased when Etomidate is combined with Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etomidate.Approved, Investigational
LandiololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Landiolol.Investigational
LanicemineThe risk or severity of adverse effects can be increased when Etomidate is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Etomidate is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Etomidate.Approved, Investigational
LevobetaxololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Levobetaxolol.Approved, Investigational
LevobunololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Levobunolol.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Etomidate is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Etomidate.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Etomidate.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Etomidate is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etomidate.Approved
LincomycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Etomidate is combined with Linezolid.Approved, Investigational
LisurideLisuride may increase the hypertensive and vasoconstricting activities of Etomidate.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Etomidate is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Etomidate is combined with Lithium cation.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Lofentanil.Illicit
LofepramineThe risk or severity of hypertension can be increased when Lofepramine is combined with Etomidate.Experimental
LofexidineThe therapeutic efficacy of Etomidate can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Etomidate.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etomidate.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Lormetazepam.Approved
LortalamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Lortalamine.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Etomidate.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etomidate.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the hypertensive and vasoconstricting activities of Etomidate.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Etomidate is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Etomidate can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Etomidate.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Etomidate is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Etomidate is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Etomidate.Approved
MedazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Medifoxamine.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Etomidate is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of hypertension can be increased when Melitracen is combined with Etomidate.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Melperone.Approved, Investigational
MephenesinThe risk or severity of adverse effects can be increased when Etomidate is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Mephenoxalone.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Etomidate is combined with Mephenytoin.Investigational, Withdrawn
MepindololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Mepindolol.Experimental
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etomidate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Etomidate is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etomidate.Approved
MetergolineMetergoline may increase the hypertensive and vasoconstricting activities of Etomidate.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Etomidate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etomidate.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Etomidate.Approved
MethotrimeprazineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etomidate.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylene blue.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Etomidate.Approved
MethylpentynolThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylphenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Etomidate is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideMethysergide may increase the hypertensive and vasoconstricting activities of Etomidate.Approved
MetipranololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Metipranolol.Approved
MetocurineThe risk or severity of adverse effects can be increased when Etomidate is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Etomidate is combined with Metocurine Iodide.Approved, Withdrawn
MetoprololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Metoprolol.Approved, Investigational
MetyrosineEtomidate may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Mianserin.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when Etomidate is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Etomidate.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Etomidate is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Etomidate is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Investigational
MirtazapineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Etomidate is combined with Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Etomidate is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Etomidate is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Etomidate is combined with Moclobemide.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Etomidate.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Etomidate is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Etomidate is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Investigational
NadololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Nadolol.Approved
NaftidrofurylThe risk or severity of adverse effects can be increased when Etomidate is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etomidate.Approved
NaluzotanThe risk or severity of adverse effects can be increased when Etomidate is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Etomidate is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Neamine.Experimental
NebivololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Etomidate is combined with Nefiracetam.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Etomidate is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Etomidate is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Etomidate is combined with Netilmicin.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Etomidate is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Niaprazine.Experimental
NicardipineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the hypertensive and vasoconstricting activities of Etomidate.Approved, Investigational
NiguldipineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Niguldipine.Experimental
NisoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etomidate.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Etomidate.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Etomidate is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Nordazepam.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Normethadone.Approved, Illicit
NortriptylineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Etomidate is combined with Octamoxin.Withdrawn
OlanzapineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etomidate.Approved
OndansetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Ondansetron.Approved
OpipramolThe risk or severity of hypertension can be increased when Opipramol is combined with Etomidate.Investigational
OpiumThe risk or severity of adverse effects can be increased when Etomidate is combined with Opium.Approved, Illicit
OrphenadrineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Etomidate is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Etomidate is combined with Osanetant.Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of hypertension can be increased when Oxaprotiline is combined with Etomidate.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etomidate.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxprenololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etomidate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etomidate.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxypertine.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PaliperidoneThe therapeutic efficacy of Etomidate can be decreased when used in combination with Paliperidone.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Pancuronium.Approved
ParaldehydeEtomidate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Etomidate is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Paroxetine.Approved, Investigational
PenbutololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Etomidate is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Penimepicycline.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etomidate.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etomidate.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
PerazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Perazine.Approved, Investigational
PergolidePergolide may increase the hypertensive and vasoconstricting activities of Etomidate.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etomidate.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etomidate.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Etomidate is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etomidate.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenoperidine.Experimental
PhenoxybenzamineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Phenoxybenzamine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Etomidate is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Etomidate is combined with Phentermine.Approved, Illicit
PhentolamineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Etomidate.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Etomidate is combined with Piclozotan.Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Etomidate.Approved
PinazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Pinazepam.Experimental
PindololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Etomidate.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Etomidate is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Pirlindole.Approved
PivagabineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pivhydrazine.Withdrawn
PizotifenThe therapeutic efficacy of Etomidate can be decreased when used in combination with Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Etomidate is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Etomidate is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etomidate.Approved
PractololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Practolol.Approved
PramipexoleEtomidate may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Prazepam.Approved, Illicit
PrazosinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Prazosin.Approved
PregabalinThe therapeutic efficacy of Etomidate can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Etomidate is combined with Pridinol.Experimental
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Etomidate.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Etomidate is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etomidate.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Etomidate is combined with Progabide.Approved, Investigational
PromazineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Etomidate.Approved, Investigational
PropafenoneThe therapeutic efficacy of Etomidate can be decreased when used in combination with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Etomidate is combined with Propanidid.Experimental
PropericiazineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Propericiazine.Approved, Investigational
PropiomazineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Propiopromazine.Vet Approved
PropiverineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Etomidate.Approved, Investigational, Vet Approved
PropranololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Etomidate is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of hypertension can be increased when Protriptyline is combined with Etomidate.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Etomidate is combined with Proxibarbal.Experimental
PRX-08066The risk or severity of adverse effects can be increased when Etomidate is combined with PRX-08066.Investigational
PsilocybineThe risk or severity of adverse effects can be increased when Etomidate is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Etomidate is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Etomidate is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Etomidate.Approved, Illicit
QuetiapineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Quetiapine.Approved
QuinidineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Quinidine.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Etomidate is combined with Quinine.Approved
QuinupramineThe risk or severity of hypertension can be increased when Quinupramine is combined with Etomidate.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Etomidate is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Ramosetron.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Etomidate is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Etomidate is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etomidate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Etomidate is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Etomidate is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etomidate.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Ribostamycin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Riluzole.Approved, Investigational
RisperidoneThe therapeutic efficacy of Etomidate can be decreased when used in combination with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Ritanserin.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Etomidate is combined with Rizatriptan.Approved
RocuroniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Etomidate is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Romifidine.Vet Approved
RopiniroleEtomidate may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineEtomidate may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Etomidate is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Etomidate.Approved
SafinamideThe risk or severity of adverse effects can be increased when Etomidate is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Safrazine.Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Etomidate is combined with Saredutant.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etomidate.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etomidate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Etomidate is combined with Selegiline.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Etomidate is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etomidate.Approved, Vet Approved
SibutramineSibutramine may increase the tachycardic activities of Etomidate.Approved, Illicit, Investigational, Withdrawn
SilodosinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Silodosin.Approved
SisomicinThe risk or severity of adverse effects can be increased when Etomidate is combined with Sisomicin.Investigational
Sodium oxybateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SotalolThe therapeutic efficacy of Etomidate can be decreased when used in combination with Sotalol.Approved
SpironolactoneThe therapeutic efficacy of Etomidate can be decreased when used in combination with Spironolactone.Approved
St. John's WortThe risk or severity of adverse effects can be increased when Etomidate is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Etomidate.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Etomidate is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Etomidate is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etomidate.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Etomidate is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Etomidate is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Etomidate is combined with Sumatriptan.Approved, Investigational
SuvorexantEtomidate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Etomidate is combined with Talbutal.Approved, Illicit
TalinololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Talinolol.Investigational
TalopramThe risk or severity of adverse effects can be increased when Etomidate is combined with Talopram.Experimental
TamsulosinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Etomidate is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Etomidate is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Etomidate is combined with Tegaserod.Approved, Investigational, Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Etomidate.Approved, Investigational
TerazosinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Terazosin.Approved
TergurideTerguride may increase the hypertensive and vasoconstricting activities of Etomidate.Experimental
TertatololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Tertatolol.Experimental
TetracyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrodotoxin.Investigational
ThalidomideEtomidate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiopropazate.Experimental
ThioproperazineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Thioproperazine.Approved
ThioridazineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etomidate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Etomidate.Approved, Investigational
TianeptineThe risk or severity of hypertension can be increased when Tianeptine is combined with Etomidate.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiapride.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tilidine.Experimental
TimololThe therapeutic efficacy of Etomidate can be decreased when used in combination with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etomidate.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Tobramycin.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Etomidate is combined with Tofisopam.Approved
TolazolineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etomidate.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Tolperisone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Etomidate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Etomidate.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Etomidate.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Etomidate is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Etomidate is combined with Triclofos.Withdrawn
TrifluoperazineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Trimazosin.Experimental
TrimethadioneThe risk or severity of adverse effects can be increased when Etomidate is combined with Trimethadione.Approved
TrimipramineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Etomidate.Approved
TropisetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Tropisetron.Approved, Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tubocurarine.Approved
UrapidilThe therapeutic efficacy of Etomidate can be decreased when used in combination with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Etomidate is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Etomidate is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Etomidate is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Etomidate is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Etomidate is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Etomidate is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Veralipride.Experimental
VerapamilThe therapeutic efficacy of Etomidate can be decreased when used in combination with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Etomidate.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Etomidate is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Vinylbital.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Vortioxetine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Etomidate is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when Etomidate is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Etomidate is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Etomidate is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etomidate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Etomidate.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Zimelidine.Withdrawn
ZiprasidoneThe therapeutic efficacy of Etomidate can be decreased when used in combination with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Etomidate is combined with Zolmitriptan.Approved, Investigational
ZolpidemEtomidate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Etomidate.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Etomidate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Etomidate is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe therapeutic efficacy of Etomidate can be decreased when used in combination with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Douglas E. Raines, "ETOMIDATE ANALOGUES THAT DO NOT INHIBIT ADRENOCORTICAL STEROID SYNTHESIS." U.S. Patent US20130079381, issued March 28, 2013.

US20130079381
General References
Not Available
External Links
Human Metabolome Database
HMDB0014437
KEGG Drug
D00548
KEGG Compound
C07522
PubChem Compound
667484
PubChem Substance
46507012
ChemSpider
580864
BindingDB
50125935
ChEBI
4910
ChEMBL
CHEMBL681
Therapeutic Targets Database
DAP000669
PharmGKB
PA164743987
Drugs.com
Drugs.com Drug Page
Wikipedia
Etomidate
ATC Codes
N01AX07 — Etomidate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3Active Not RecruitingTreatmentCritical Illness1
3RecruitingTreatmentStrokes1
3WithdrawnNot AvailableHigh Blood Pressure (Hypertension)1
4Active Not RecruitingTreatmentAnaesthesia therapy / Electroconvulsive Therapy1
4CompletedPreventionAdrenocortical Deficiency / Hemodynamics Instability1
4CompletedPreventionInduction of Anaesthesia1
4CompletedTreatmentAirway Control / Anaesthesia therapy / Complications / Intubations1
4CompletedTreatmentCholangiocarcinomas / Choledocholithiasis / Malignant Neoplasm of Pancreas / Pancreatitis1
4CompletedTreatmentConscious Sedation Failure During Procedure1
4CompletedTreatmentCoronary Artery Disease / Mitral Valve Regurgitation1
4CompletedTreatmentCoronary Artery Disease / Valvular Heart Disease1
4CompletedTreatmentIntubation; Difficult1
4CompletedTreatmentSurgery, Cardiac1
4Not Yet RecruitingTreatmentDelirium / Hemodynamics Instability1
4Not Yet RecruitingTreatmentMyoclonus1
4RecruitingTreatmentCardio-respiratory arrest / Respiratory Arrest1
4RecruitingTreatmentDepression1
4RecruitingTreatmentIntubation Complications1
4Unknown StatusTreatmentAnaesthesia therapy / Hemodynamics / Oxidative Stress1
4Unknown StatusTreatmentAnaesthesia therapy / Pregnancy Termination1
4Unknown StatusTreatmentBispectral Index / Etomidate / Induction / Pediatric1
4Unknown StatusTreatmentCongenital Choledochal Cyst / Congenital Hydronephrosis / Fracture Bone1
4Unknown StatusTreatmentCoronary Artery Bypass Surgery1
4Unknown StatusTreatmentHemodynamics / Hysteroscopy / Sedation therapy1
4Unknown StatusTreatmentAdjunct to general anesthesia therapy / Target Controlled Infusion (TCI)1
Not AvailableCompletedNot AvailableNeuromuscular Monitoring1
Not AvailableCompletedBasic ScienceDepression1
Not AvailableCompletedPreventionAdrenal Insufficiency1
Not AvailableCompletedTreatmentComplication of Gastrostomy1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentSepsis / Traumas1
Not AvailableRecruitingTreatmentIschemia, Brain / Strokes1
Not AvailableRecruitingTreatmentPostoperative Complications1
Not AvailableWithdrawnNot AvailableTraumas1

Pharmacoeconomics

Manufacturers
  • Hospira inc
  • Bedford laboratories div ben venue laboratories inc
  • Parenta pharmaceuticals inc
  • Pharmaforce inc
Packagers
  • American Regent
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Ebewe Pharma
  • General Injectables and Vaccines Inc.
  • Hospira Inc.
Dosage forms
FormRouteStrength
InjectionIntravenous2 mg/mL
Injection, solutionIntravenous2 mg/mL
Injection, solutionIntravenous20 mg/10mL
Injection, solutionIntravenous40 mg/20mL
SolutionIntravenous2 mg/mL
Prices
Unit descriptionCostUnit
Amidate 2 mg/ml vial1.55USD ml
Amidate 2 mg/ml ampul1.19USD ml
Etomidate 2 mg/ml vial1.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)142-142.8Godefroi, E.F. and Van Der Eijcken, C.A.M.; U.S. Patent 3,354,173; November 21, 1967; assigned to Janssen Pharrnaceutica NV (Belgium).
water solubility63.2 mg/LNot Available
logP3.05POMONA (1987)
Predicted Properties
PropertyValueSource
Water Solubility0.477 mg/mLALOGPS
logP2.66ALOGPS
logP2.5ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)4.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area44.12 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity69.59 m3·mol-1ChemAxon
Polarizability26.43 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9908
Blood Brain Barrier+0.95
Caco-2 permeable+0.6275
P-glycoprotein substrateNon-substrate0.7386
P-glycoprotein inhibitor INon-inhibitor0.8567
P-glycoprotein inhibitor IINon-inhibitor0.8597
Renal organic cation transporterNon-inhibitor0.7918
CYP450 2C9 substrateNon-substrate0.7947
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.7671
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.5432
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8357
Ames testNon AMES toxic0.7989
CarcinogenicityNon-carcinogens0.8795
BiodegradationNot ready biodegradable0.5121
Rat acute toxicity2.5459 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9622
hERG inhibition (predictor II)Non-inhibitor0.8553
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbonylimidazoles. These are substituted imidazoles in which the imidazole ring bears a carbonyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
Carbonylimidazoles
Alternative Parents
N-substituted imidazoles / Benzene and substituted derivatives / Heteroaromatic compounds / Carboxylic acid esters / Monocarboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides
show 1 more
Substituents
Imidazole-4-carbonyl group / Monocyclic benzene moiety / Benzenoid / N-substituted imidazole / Heteroaromatic compound / Carboxylic acid ester / Carboxylic acid derivative / Monocarboxylic acid or derivatives / Azacycle / Organic nitrogen compound
show 7 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
ethyl ester, imidazoles (CHEBI:4910)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Martin LJ, Oh GH, Orser BA: Etomidate targets alpha5 gamma-aminobutyric acid subtype A receptors to regulate synaptic plasticity and memory blockade. Anesthesiology. 2009 Nov;111(5):1025-35. doi: 10.1097/ALN.0b013e3181bbc961. [PubMed:19809285]
  4. Desai R, Ruesch D, Forman SA: Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity. Anesthesiology. 2009 Oct;111(4):774-84. doi: 10.1097/ALN.0b013e3181b55fae. [PubMed:19741491]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Creagh O, Torres H, Rodriguez N, Gatica SR: Alpha-2B adrenergic receptor mediated hemodynamic profile of etomidate. P R Health Sci J. 2010 Jun;29(2):91-5. [PubMed:20496522]
  2. Paris A, Philipp M, Tonner PH, Steinfath M, Lohse M, Scholz J, Hein L: Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology. 2003 Oct;99(4):889-95. [PubMed:14508322]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic transporter activity
Specific Function
Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including b...
Gene Name
SLC2A1
Uniprot ID
P11166
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 1
Molecular Weight
54083.325 Da
References
  1. Stephenson KN, Croxen RL, El-Barbary A, Fenstermacher JD, Haspel HC: Inhibition of glucose transport and direct interactions with type 1 facilitative glucose transporter (GLUT-1) by etomidate, ketamine, and propofol: a comparison with barbiturates. Biochem Pharmacol. 2000 Sep 1;60(5):651-9. [PubMed:10927023]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:18